Table 1.
Baseline Characteristics of the Patients
| Variable | Non-current Smokers | Cigarettes per Day | ||||
|---|---|---|---|---|---|---|
| 0-9 | 10-19 | 20-29 | ≥30 | P-value | ||
| Number | 1732 | 206 | 354 | 715 | 422 | |
| Cigarettes per day, median (IQR) | n/a | 5 (2-6) | 10 (10-15) | 20 (20-20) | 40 (30-40) | n/a |
| Age, years±SD | 61.1±9.6 | 58.3±10.45 | 54.5±10.5 | 53.1±9.2 | 52.0±8.3 | <.0001 |
| Male sex, % | 77.0 | 81.1 | 72.6 | 83.9 | 93.6 | <.0001 |
| Region, % | ||||||
| North America and Northern and Western Europe | 53.2 | 47.1 | 55.1 | 46.9 | 40.3 | <.0001 |
| Southern and Eastern Europe | 24.5 | 26.7 | 22.0 | 29.0 | 32.7 | 0.0007 |
| Latin America | 13.6 | 18.4 | 13.8 | 13.0 | 13.0 | 0.5855 |
| Middle East and Australasia | 8.7 | 7.8 | 9.0 | 11.2 | 14.0 | 0.0009 |
| Hypertension, % | 50.8 | 45.6 | 40.9 | 34.7 | 33.3 | <.0001 |
| Hyperlipidemia, % | 41.3 | 34.1 | 38.3 | 35.9 | 35.1 | 0.0442 |
| Diabetes mellitus, % | 20.7 | 18.1 | 9.5 | 11.9 | 14.5 | <.0001 |
| Killip Class II-IV, % | 7.4 | 9.3 | 7.9 | 9.8 | 6.9 | 0.2726 |
| Anterior MI, % | 44.7 | 41.3 | 35.3 | 36.8 | 35.8 | <.0001 |
| Time from symptom onset to start of fibrinolytic, hours (IQR) | 2.7 (1.8-4.2) | 2.9 (2.0-4.4) | 2.6 (1.6-3.8) | 2.7 (1.8-4.2) | 2.5 (1.7-3.8) | 0.2353 |
| Fibrin-specific lytic, % | 70.6 | 68.4 | 68.4 | 61.8 | 70.4 | 0.0009 |
| Initial heparin, % | ||||||
| Unfractionated heparin | 46.2 | 45.6 | 43.2 | 42.8 | 50.0 | 0.1581 |
| Low-molecular-weight heparin | 30.1 | 30.1 | 30.2 | 28.1 | 30.1 | 0.8917 |
| Both | 4.8 | 3.9 | 6.5 | 5.2 | 3.8 | 0.4508 |
| Neither | 18.9 | 20.4 | 20.1 | 23.9 | 16.1 | 0.0158 |
| Concurrent administration of a CYP3A4-metabolized statin*, % | 60.6 | 57.6 | 58.5 | 60.6 | 60.0 | 0.8413 |
*
Includes atorvastatin, simvastatin, and lovastatin.